ClinicalTrials.gg
RecruitingNCT05243134Updated Feb 16, 2022

The Influence of Anatomic Deformities on the Clinical Efficacy in the Patients With Patellar Dislocation

An observational study in Patellar Dislocation, Anatomic Abnormality and Trochlear Dysplasia, sponsored by Peking University Third Hospital. Recruiting at 1 site in China. Open to participants aged 14 Years to 40 Years. Per ClinicalTrials.gov, last updated 2022-02-16.

Sponsored by Peking University Third Hospital · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Sep 2021; still recruiting 5 years 1 month later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
14 Years to 40 Years
Sex
All
01

Study summary

All the data of patients with patellar dislocation will be collected to evaluate the anatomic deformities. The data includes X-ray, CT, MRI examinations, medical records, and physical examination information. Finally, we correlate the anatomic deformities with clinical efficacy. To search for the risk factors that lead to patellar dislocation and influence the therapeutic effect.

02

Conditions studied

  • Patellar Dislocation
  • Anatomic Abnormality
  • Trochlear Dysplasia
  • Femoral Anteversion
  • Treatment
  • Sport Injury

Keywords

  • Patellar dislocation
  • Anatomic deformity
  • trochlear dysplasia
  • treatment
03

In context

Patellar Dislocation

41 studies on the registry are indexed under Patellar Dislocation; 9 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 100 across 15 observational studies indexed under Patellar Dislocation.

Browse Patellar Dislocation studies →

Lead sponsor

Peking University Third Hospital is the lead sponsor of 752 studies on the registry; 273 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with patellar dislocation

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-Patients with patellar dislocation.

Exclusion criteria

Exclusion Criteria:

  • Patients with significant ligamentous knee injury.
  • Previous fracture or surgery of the lower limb.
  • Patellar dislocation caused by car accidents or other high-energy force directly on the patella.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Study Group

    Patients with at least one type of anatomic deformity

    Other: Collect the clinical data

  • Control group

    Patients without anatomic deformity

    Other: Collect the clinical data

Interventions

  • OtherCollect the clinical data

    We analyze the influence of the anatomic deformity on the clinical efficacy at the follow-up.

06

What researchers measure

Primary outcomes

  1. Number of participants with redislocation of their patella after surgery as confirmed by clinical physical examination

    We can determine patellar redislocation by physical examination. In participants with redislocation of their patella, the patella (kneecap) slips out of its normal position. Often the knee is partly bent, painful and swollen.The patella is also often felt and seen out of place. We recored the number of participants with redislocation of their patella after surgery.

    Time frame: Three years after surgery

  2. International Knee Documentation Committee(IKDC) score

    The entire IKDC form, which includes a demographic form, current health assessment form, subjective knee evaluation form, knee history form, surgical documentation form, and knee examination form, may be used as separate forms. The knee history form and surgical documentation form are provided for convenience. All researchers are required to complete the subjective knee evaluation and knee examination form. Instructions for scoring the subjective knee evaluation form and the knee examination form are provided on the back of the forms. Total score 100, ≥75 being considered excellent.

    Time frame: Three years after surgery

  3. Magnatic Resonance Imaging evaluation

    All patients undergoing anterior cruciate ligament reconstruction underwent MRI imaging evaluation of both knees. Use International Cartilage Repair Society(ICRS) score to evaluate, total score is 12, classified into four grades,grade Ⅰ: normal (12), grade Ⅱ: nearly normal (8-11), grade Ⅲ: abnormal (4-7), grade Ⅳ: severely abnormal (1-3).

    Time frame: Three years after surgery

Secondary outcomes

  1. Skeletal force line and various angles by X-ray evaluation

    X-ray was used to evaluate the skeletal force line and various angles of patients. Use Qvadriceps Angle to evaluate quadriceps force line and patellar ligament force line. The normal Angle is 18-22° for the adult standing position.Above or below this range is considered abnormal.

    Time frame: Preoperative

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Xu Z, Song Y, Deng R, Ye J, Wang X, Wang H, Yu JK. CT and MRI measurements of tibial tubercle lateralization in patients with patellar dislocation were not equivalent but could be interchangeable. Knee Surg Sports Traumatol Arthrosc. 2023 Jan;31(1):349-357. doi: 10.1007/s00167-022-07119-8. Epub 2022 Sep 11. PubMed 36088618 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2021 (actual). Primary completion is estimated for Dec 2025, 51 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2021
First posted
Feb 16, 2022
StartActual
Sep 30, 2021
Primary completionEst.
Dec 30, 2025
CompletionEst.
Dec 30, 2025
Last update
Feb 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05243134
Responsible party
Sponsor
First posted
Feb 16, 2022
Start date
Sep 30, 2021
Primary completion
Dec 30, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Feb 16, 2022

Study contacts

Jia_kuo Yu
Contact
yujiakuo@126.com
01082267392
Lin Lin
Contact
01082267392
Lin Lin
study director · Peking University Third Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion